Targeting brain metastases in patients with melanoma.
Patients with brain metastases from malignant melanoma historically have a very poor outcome. Surgery and radiotherapy can be used, but for the majority of patients the disease will progress quickly. In the recent past, patients with brain metastases derived only minimal benefit from cytotoxic chemotherapy. Novel therapies that have been shown to be superior to chemotherapy in metastatic melanoma have made their way in clinic and data regarding their use in patients with treated or untreated brain metastases are encouraging. In this paper we describe the use of vemurafenib, dabrafenib, and ipilimumab in patients with melanoma disseminated to the brain in addition to other treatments currently in development.
Medical Oncology Department, Guy's and St Thomas' NHS Foundation Trust, UK.
Dionysis
D
Papadatos-Pastos
Medical Oncology Department, Guy's and St Thomas' NHS Foundation Trust, UK.
Aspasia
A
Soultati
Medical Oncology Department, Guy's and St Thomas' NHS Foundation Trust, UK.
Mark
M
Harries
D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary; D003131:Combined Modality Therapy; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007211:Indoles / Q000008:administration & dosage; D000074324:Ipilimumab; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D009154:Mutation; D010091:Oximes / Q000008:administration & dosage; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000008:administration & dosage; D000077484:Vemurafenib
D000911:Antibodies, Monoclonal; D007093:Imidazoles; D007211:Indoles; D000074324:Ipilimumab; D010091:Oximes; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib